Table 3.
Characteristics | EMVI − | EMVI + | p |
---|---|---|---|
Age (years), Me (Q1; Q3) | 65.90 (58.75; 74.00) | 64.90 (59.48; 71.76) | 0.667 |
Sex (female), n (%) | 43 (41.0) | 30 (38.5) | 0.8512 |
Tumor, n (%) | |||
T2-T3 | 96 (91.4) | 50 (65.8) | <0.0012 |
T4 | 9 (8.6) | 26 (34.2) | |
Lymph nodes, n (%) | |||
N0 | 49 (52.7) | 19 (26.4) | <0.0012 |
N1 | 35 (37.6) | 28 (38.9) | |
N2 | 9 (9.7) | 25 (34.7) | |
Stage, n (%) | |||
II-III A | 59 (57.8) | 25 (32.9) | <0.0012 |
III B | 38 (37.3) | 27 (35.5) | |
III C | 5 (4.9) | 24 (31.6) | |
ALC (109/L), Me (Q1; Q3) | 1.70 (1.33; 2.24) | 1.90 (1.45; 2.26) | 0.217 |
AMC (109/L), Me (Q1; Q3) | 0.58 (0.46; 0.80) | 0.63 (0.53; 0.75) | 0.181 |
ANC (109/L), Me (Q1; Q3) | 4.49 (3.62; 5.81) | 5.10 (4.07; 6.16) | 0.041 |
Platelets (109/L), Me (Q1; Q3) | 253.50 (217.00; 313.25) | 303.00 (249.50; 361.75) | 0.001 |
LMR, Me (Q1; Q3) | 2.90 (2.30; 3.83) | 2.86 (2.20; 3.79) | 0.885 |
NLR, Me (Q1; Q3) | 2.54 (2.05; 3.31) | 2.82 (2.18; 3.43) | 0.189 |
PLR, Me (Q1; Q3) | 150.70 (115.97; 200.00) | 167.19 (119.95; 218.05) | 0.293 |
LMR above median, n (%) | 53 (50.0) | 38 (48.7) | 0.9822 |
NLR above median, n (%) | 49 (46.2) | 43 (55.1) | 0.2962 |
PLR above median, n (%) | 49 (46.2) | 43 (55.1) | 0.2962 |
CEA, Me (Q1; Q3) | 3.62 (2.24; 6.97) | 5.63 (3.07; 9.68) | 0.027 |
CA19-9, Me (Q1; Q3) | 9.87 (5.36; 15.76) | 11.71 (2.77; 18.29) | 0.741 |
Bold font indicates statistical significance. EMVI, extramural vascular invasion; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-monocyte ratio; PLR, platelet-to-lymphocyte ratio; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; Q, quartile; Me, median. Differences in the level of quantitative variables between groups were analysed with Mann–Whitney’s U test, dependencies between qualitative variables and groups were analysed with chi-square test2 (with Yate’s correction for continuity for 2 × 2 tables).